Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
06 June 2023 - 5:00PM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced they will be
showcasing their automated workflow solutions for streamlining
discovery workflows in antibody and therapeutics development at
Antibody Engineering and Therapeutics, Europe in Amsterdam, The
Netherlands. In addition to the exhibition, Jason Lehmann, PhD
Senior Product Marketing Manager at Telesis Bio will present “The
BioXp® System: Accelerating Hit-to-Lead Discovery by Breaking
Through Critical Synthesis Bottlenecks” in the opening day session.
The award winning BioXp® system and associated BioXp De novo
kits and BioXp Select kits enable push-button, automated synthesis
of gene fragments, clones, variant libraries and mRNA from input
sequence or existing DNA. In May, Telesis Bio also introduced their
first automated NGS Library Preparation kit for Plasmid Sequencing
on the BioXp platform, further advancing the vision of the platform
as a total solution for streamlining molecular biology workflows.
The BioXp system empowers researchers in antibody therapeutics to
overcome traditional bottlenecks in lead discovery programs and
take control of their synthesis timelines by enabling automated and
efficient synthesis and sequence confirmation of antibody
candidates.
For more information on solutions for accelerating workflows in
therapeutic antibody development,
please visit https://telesisbio.com/workflows/synthetic-dna/antibody-drug-discovery/
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
Forward-Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements and guidance regarding the anticipated use of
proceeds from the financing, as well as statements regarding the
future release and success of new and existing products and
services. Such statements are based on current assumptions that
involve risks and uncertainties that could cause actual outcomes
and results to differ materially. These risks and uncertainties,
many of which are beyond our control, include risks described in
the section entitled Risk Factors and elsewhere in our Annual
Report on Form 10-K, which was filed with the Securities and
Exchange Commission (SEC) on March 22, 2023, as amended on May 17,
2023 and in our Quarterly Report on Form 10-Q, which was filed with
the SEC on May 12, 2023. These forward-looking statements speak
only as of the date hereof and should not be unduly relied upon.
Telesis Bio disclaims any obligation to update these
forward-looking statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024